Alto Neuroscience Inc. (ANRO)
NYSE NYSE Primary 
Alto Neuroscience, Inc. (ANRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / November 5, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO). Investors who purchased Alto Neuroscience securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ANRO.
Did Alto Neuroscience, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate- ANRO
NEW YORK, NY / ACCESSWIRE / November 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alto Neuroscience, Inc. ("Alto Neuroscience, Inc.") (NYSE:ANRO) concerning possible violations of federal securities laws. Alto Neuroscience announced on October 22, 2024, that "the Phase 2b study of ALTO-100 in patients with major depressive disorder (MDD) did not meet its primary endpoint, assessed by a change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS), compared to placebo.
Alto Neuroscience Inc Is Being Investigated For Securities Law Violations And Investors With Losses Are Encouraged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / November 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Alto Neuroscience, Inc. (ANRO) And Encourages Investors to Connect
NEW YORK CITY, NY / ACCESSWIRE / November 4, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO). Investors who purchased Alto Neuroscience securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ANRO.
Alto Neuroscience, Inc. (ANRO) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
NEW YORK, NY / ACCESSWIRE / November 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alto Neuroscience, Inc. ("Alto Neuroscience, Inc.") (NYSE:ANRO) concerning possible violations of federal securities laws. Alto Neuroscience announced on October 22, 2024, that "the Phase 2b study of ALTO-100 in patients with major depressive disorder (MDD) did not meet its primary endpoint, assessed by a change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS), compared to placebo.
The Schall Law Firm Urges Shareholders To Join An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / November 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Alto Neuroscience, Inc. (ANRO) And Encourages Investors to Reach Out
NEW YORK CITY, NY / ACCESSWIRE / November 3, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO). Investors who purchased Alto Neuroscience securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ANRO.
Alto Neuroscience Inc Is Being Investigated For Securities Law Violations And Investors With Losses Are Encouraged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / November 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Alto Neuroscience, Inc. (ANRO) And Encourages Stockholders to Reach Out
NEW YORK CITY, NY / ACCESSWIRE / November 1, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO). Investors who purchased Alto Neuroscience securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ANRO.
Investors Who Lost Money on Alto Neuroscience, Inc. Should Contact Levi & Korsinsky about an Ongoing Investigation - ANRO
NEW YORK, NY / ACCESSWIRE / November 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alto Neuroscience, Inc. ("Alto Neuroscience, Inc.") (NYSE:ANRO) concerning possible violations of federal securities laws. Alto Neuroscience announced on October 22, 2024, that "the Phase 2b study of ALTO-100 in patients with major depressive disorder (MDD) did not meet its primary endpoint, assessed by a change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS), compared to placebo.
Shareholder Rights Advocates at Levi & Korsinsky Investigate Alto Neuroscience, Inc. (ANRO) Regarding Possible Securities Fraud Violations
NEW YORK, NY / ACCESSWIRE / October 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alto Neuroscience, Inc. ("Alto Neuroscience, Inc.") (NYSE:ANRO) concerning possible violations of federal securities laws. Alto Neuroscience announced on October 22, 2024, that "the Phase 2b study of ALTO-100 in patients with major depressive disorder (MDD) did not meet its primary endpoint, assessed by a change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS), compared to placebo.
Alto Neuroscience, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - ANRO
NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alto Neuroscience, Inc. ("Alto Neuroscience, Inc.") (NYSE:ANRO) concerning possible violations of federal securities laws. Alto Neuroscience announced on October 22, 2024, that "the Phase 2b study of ALTO-100 in patients with major depressive disorder (MDD) did not meet its primary endpoint, assessed by a change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS), compared to placebo.
